Hostname: page-component-54dcc4c588-xh45t Total loading time: 0 Render date: 2025-10-14T03:58:35.141Z Has data issue: false hasContentIssue false

Neuronal synaptic autoantibodies and PsycHosis: Prognostic factors for the diagnosis of autoimmune encephalitis in patients with psychotic spectrum disorders -The PHLAMES Study

Published online by Cambridge University Press:  26 August 2025

A. Pigoni*
Affiliation:
Neuroscience, IRCCS Fondazione Ca Granda Policlinico Hospital, Milan, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Abstract: Background

The recent years witnessed an increase in the knowledge regarding autoimmune encephalitis (AE). These autoimmune entities often present with mixed psychiatric and neurologic features and in up to 4% of the cases the presentation is purely psychiatric. The diagnosis can be made only through the discovery of Neuronal Surface Autoantibodies (NSAbs) in the Cerebro Spinal Fluid, but symptoms and signs of possible and probable diagnosis have been described (Pollack et al., 2020). However, NSAbs can be found also in peripheral blood in various percentage of patients. The role of these antibodies in psychiatric patients is yet not known.

The PHLAMES study aims at evaluating first episode psychosis (FEP) patients for signs and symptoms of AE in a psychiatric setting, with the double objective of assessing the diagnosis of AE and the role of circulating NSAbs in psychiatric patients, through clinical evaluation, biological samples, and neuroimaging.

Methods

In the PHLAMES study, all patients with FEP (<6 months from the onset) were tested with a diagnostic algorithm for signs or symptoms of AE. A complete psychiatric and neurologic assessment was performed; cognitive tests were administered. All patients underwent blood sample to test for circulating auto-antibodies against SNC structures.

A subsample also underwent MRI, including gadolinium contrast.

Analyses compared patients testing positive for serum NSAbs (NSAbs-POS) to those tested negative (NSAbs-Neg).

Results

12.8% of the patients tested positive for serum NSAbs (NSAbs-POS). No difference in terms of age, sex, BMI, years od education, and ethnicity was found between groups.

Regarding the neurologic variables, NSAbs-POS significantly showed more memory deficits, parkinsonism signs, and speech disorders (p<0.001), compared to NSAbs-NEG patients. Similarly, NSAbs-POS patients presented a significant in TMT-A, Raven, and RAVLT scores (p<0.05) compared to NSAbs-NEG. Finally, NSAbs-POS patients presented an increased score at PANSS Somatic implication item and a reduced score at PANSS Insight (p<0.05) items, suggesting a higher concern of these patients regarding their help and a greater awareness of their condition.

Regarding MRI, differences are present between groups, both on structural and on contrasted images.

Discussion

Our preliminary findings suggest the possibility that NSAbs-POS patients might represent a subpopulation of FEP with specific characteristics. These results are preliminary and need a confirmation in bigger samples, but they might represent a step towards the identification of clinically meaningful subgroups in FEP defined through an easy and not invasive test, helping to dissect the heterogeneity of psychiatric disorders and moving towards precision psychiatry.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.